| Drug Name |
Ziprasidone hydrochloride |
| Drug ID |
BADD_D02389 |
| Description |
Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior.[A190525] These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers.[A190525] Luckily, several treatment options for psychotic disorders have been introduced to market since the realization of chlorpromazine's antipsychotic properties in 1952.[A190525]
Second generation antipsychotics (commonly referred to as atypical antipsychotics) include [clozapine], [quetiapine], [olanzapine], [aripiprazole] and [ziprasidone] among others, and are generally thought to be as efficacious as first generation antipsychotics but differ in their adverse effect profiles.[A190525,A190534] First generation antipsychotics are associated with extrapyramidal adverse effects while atypical antipsychotics are linked to weight gain, impaired glucose tolerance and metabolic syndrome.[A190534,A190537]
Ziprasidone is used to treat schizophrenia and bipolar disorder.[A180748] It can effectively reduce the rate and time of relapses in schizophrenia, and can be used to treat manic episodes in bipolar disorder although the mechanism of action is unknown.[A180748] Although ziprasidone is classified as an atypical antipsychotic, it appears to have a lower incidence of metabolic adverse effects compared to other medications in the same class.[A190525] |
| Indications and Usage |
In its oral form, ziprasidone is approved for the treatment of schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar I disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder.[L7342] The injectable formulation is approved only for treatment of acute agitation in schizophrenia.[L7342] |
| Marketing Status |
approved |
| ATC Code |
N05AE04 |
| DrugBank ID |
DB00246
|
| KEGG ID |
D01939
|
| MeSH ID |
C092292
|
| PubChem ID |
219099
|
| TTD Drug ID |
D0R1JV
|
| NDC Product Code |
0904-6270; 42816-2002; 42816-2003; 66005-0027; 16714-837; 63187-168; 63739-508; 65862-703; 68071-2716; 68180-333; 70518-0743; 70518-0757; 0781-2167; 65862-704; 16714-835; 33342-144; 55111-259; 68180-334; 70518-2925; 0781-2168; 0904-6269; 42816-0054; 52562-010; 65862-702; 68724-5235; 16714-838; 33342-147; 59762-2004; 63629-8150; 65862-705; 70518-1604; 0049-0058; 63739-005; 68071-2715; 68180-331; 70518-0787; 70518-2374; 65372-1160; 65862-398; 0049-0054; 63739-988; 70518-2294; 71335-0501; 0781-2166; 42816-0056; 42816-2001; 42816-2004; 55111-801; 55111-257; 0049-0056; 63629-3331; 68001-452; 68071-2979; 68071-2980; 70518-2477; 70518-2622; 71335-0263; 0904-6271; 33342-145; 59762-2002; 68001-451; 68001-453; 68180-332; 70518-2940; 71335-0729; 0904-6272; 50090-4821; 50090-5420; 70518-1835; 0781-2164; 42816-0052; 33342-146; 55111-256; 68071-3418; 70518-0782; 70518-2757; 42816-0058; 16714-836; 55111-258; 63739-666; 68001-450; 71335-0585; 59762-2003 |
| UNII |
216X081ORU
|
| Synonyms |
ziprasidone | ziprazidone | 5-(2-(4-(3-benzisothiazolyl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one | ziprasidone hydrochloride | CP 88059-01 | CP-88,059-1 | CP-88,059-01 | ziprasidone hydrochloride, monohydrate | Geodon | CP 88059 | CP-88,059 |
